 BioXcel Therapeutics Inc NASDAQ: BTAI shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMI dexmedetomidine sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in. 